Phase 3 Study of ZIGAKIBART (BION-1301) in Adults with IgA Nephropathy
- Substances:ZIGAKIBART
Germany- Participants:18–64 years · 65+ years
- Substances:ZIGAKIBART
Rare diseases
Investigational molecules
Locations
GermanyStudy of Atezolizumab with Lenvatinib or Sorafenib vs Lenvatinib or Sorafenib alone in Unresectable Hepatocellular Carcinoma after Atezolizumab and Bevacizumab
GermanyEfficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
GermanyEfficacy and Safety Evaluation of Odevixibat in Pediatric Biliary Atresia Post-Kasai Hepatoportoenterostomy: A Double-Blind, Randomized, Placebo-Controlled Trial
GermanyA Phase 3 Randomized Open-Label Study of Sacituzumab Govitecan Versus Physician's Choice in Recurrent or Persistent Endometrial Cancer Post-Chemotherapy and Immunotherapy
GermanyEfficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial
GermanyA Study of CLDN6 CAR-T Cell Therapy With or Without CLDN6 RNA-LPX Vaccine in Patients With CLDN6-Positive Advanced Solid Tumors That Returned or Did Not Respond to Treatment
GermanyA study comparing BNT113 combined with pembrolizumab versus pembrolizumab alone for patients with HPV16-positive head and neck cancer that cannot be removed by surgery
Germany
GermanyLong-term study of sotatercept added to standard treatment in patients with pulmonary arterial hypertension
GermanyA study of ziltivekimab compared to placebo for reducing heart problems in patients who have had a heart attack
GermanyStudy of Rocatinlimab with Topical Treatments for Adults with Moderate to Severe Atopic Dermatitis
GermanyTell us about your condition – we search every trial in Europe and connect you with the right site.